Boston Scientific Corporation $BSX Shares Purchased by Prospera Financial Services Inc

Prospera Financial Services Inc raised its position in Boston Scientific Corporation (NYSE:BSX) by 108.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,704 shares of the medical equipment provider’s stock after purchasing an additional 14,424 shares during the quarter. Prospera Financial Services Inc’s holdings in Boston Scientific were worth $1,182,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific during the 4th quarter worth about $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific during the 4th quarter valued at about $26,000. Sfam LLC purchased a new position in Boston Scientific during the 4th quarter valued at about $29,000. Finally, Eagle Bay Advisors LLC acquired a new position in Boston Scientific in the 4th quarter valued at about $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director David C. Habiger acquired 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Cheryl Pegus acquired 1,770 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares in the company, valued at approximately $99,987.30. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 204,322 shares of company stock valued at $9,939,221. 0.34% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on BSX shares. Wells Fargo & Company cut their price target on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 30th. Weiss Ratings cut shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. Jefferies Financial Group cut their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Citigroup reduced their target price on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, Stifel Nicolaus set a $60.00 price target on shares of Boston Scientific in a research report on Wednesday, July 29th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $51.40 on Thursday. The business has a 50-day simple moving average of $45.94 and a 200-day simple moving average of $59.69. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The company has a market cap of $74.49 billion, a PE ratio of 20.81, a P/E/G ratio of 1.12 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter last year, the company earned $0.75 earnings per share. The firm’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has approved a share repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.